Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Also known as: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma / Advanced Adenocarcinoma of the Stomach, Including Gastroesophageal Junction
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB05578 | Ramucirumab | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB05578 | Ramucirumab | Vascular endothelial growth factor receptor 2 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB15765 | Sintilimab | 1 / 2 | Unknown Status | 1 |
| DB00062 | Albumin human | 2 | Recruiting | 1 |
| DB09078 | Lenvatinib | 2 | Recruiting | 1 |
| DB01229 | Paclitaxel | 2 | Recruiting | 1 |
| DB17451 | Serplulimab | 2 | Recruiting | 1 |
| DB01229 | Paclitaxel | 2 / 3 | Unknown Status | 1 |